Low-Level Light Therapy Another Option for Chemotherapy-Induced Hair Loss

A recent study evaluated the effect of red light on hair growth in women with breast cancer. This low-level light therapy (LLLT), or photobiomodulation therapy, was originally approved by the Food and Drug Administration as a treatment for both men and women with pattern baldness.
 
BY Allie Casey
PUBLISHED April 27, 2017
Chemotherapy-induced hair loss is one of the most feared treatment-related side effects among patients with cancer. Recent interventions involve cooling systems worn on the scalp to reduce the loss of hair during chemotherapy. However, there are other options that focus on improving hair recovery after the fact.
A recent study evaluated the effect of red light on hair growth in women with breast cancer. This low-level light therapy (LLLT), or photobiomodulation therapy, was originally approved by the Food and Drug Administration as a treatment for both men and women with pattern baldness.

Raymond Lanzafame, M.D., CMS director for the American Society for Laser Medicine and Surgery and researcher in the field of lasers and light applications in medicine, explained, “We hypothesized that a similar treatment strategy might be capable of stimulating hair growth in chemotherapy patients. The early results were more dramatic than we had expected.”

The study included 11 female patients with breast cancer, aged 20 to 60, who had completed adjuvant chemotherapy one to four weeks prior. After global scalp photography, researchers selected a scalp site and trimmed the remaining hair to 3 millimeter height. Baseline hair counts were at a median of 54.6 for the placebo group and 36.5 for the active group.

These patients were randomized into two groups, active treatment and placebo. The active treatment group was made up of six patients who received a bicycle-helmet-like apparatus equipped with 5 milliwatt lasers and 30 LEDs. The placebo group, five patients, received an identical device, affixed with only incandescent lights. Both groups used their respective device at home for 25 minutes, every other day. Follow-up assessment was done at three and six months.

At 12 weeks, there was a 2.8-fold percentage increased demonstrated — the placebo group had median hair counts of 199.4, while the active group were at 259.8. After 24 weeks, the active group hair counts were at 283.5, while the placebo group was at 236.3, demonstrating a 2.6-fold increase in hair counts from week 12 to week 24. No adverse events were reported.

Jeff Braile, the president of Apira Science, manufacturer of iGrow, the device used in the study, said, “The results of this study are extremely encouraging. We’ve known for some time that red light effectively treats androgenetic alopecia, but to witness that it can have a similar effect on chemotherapy-induced hair loss is groundbreaking. Hair loss as a result of breast cancer treatment can take an emotional toll on patients already going through a tough time, and we’re grateful that we can alleviate some of that burden.”

The researchers believe that these results warrant further study with larger groups.
 
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Side Effect Management CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In